埃罗替尼-话题@MedSci - 梅斯（MedSci）

[GetTopicListResponse(id=1582331, encodeId=3cab15823312e, content=<a href='/topic/show?id=020e415e867' target=_blank style='color:#2F92EE;'>#埃罗替尼#</a>, objectTitle=Lancet Oncol：埃罗替尼+雷莫芦单抗治疗EGFR突变型转移性NSCLC, objectType=article, longId=180839, objectId=78aa180839bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78aa180839bf, replyNumber=0, likeNumber=62, createdTime=2019-10-11, rootId=0, userName=luckyshitiancai_42705689, userId=1dc016903257, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78aa180839bf, moduleTitle=Lancet Oncol：埃罗替尼+雷莫芦单抗治疗EGFR突变型转移性NSCLC, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=78aa180839bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1582330, encodeId=614915823305c, content=<a href='/topic/show?id=020e415e867' target=_blank style='color:#2F92EE;'>#埃罗替尼#</a>, objectTitle=MOL CANCER THER：非小细胞肺癌细胞对EGFR -酪氨酸激酶抑制剂埃罗替尼的敏感性, objectType=article, longId=100144, objectId=644a100144e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=644a100144e7, replyNumber=0, likeNumber=56, createdTime=2017-05-31, rootId=0, userName=luckyshitiancai_42705689, userId=1dc016903257, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=644a100144e7, moduleTitle=MOL CANCER THER：非小细胞肺癌细胞对EGFR -酪氨酸激酶抑制剂埃罗替尼的敏感性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=644a100144e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1582329, encodeId=3bf015823298e, content=<a href='/topic/show?id=020e415e867' target=_blank style='color:#2F92EE;'>#埃罗替尼#</a>, objectTitle=Lancet Respir Med：埃罗替尼与贝伐单抗联合用药使非小细胞肺癌T790M突变患者获益, objectType=article, longId=98017, objectId=688e9801ee7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=688e9801ee7, replyNumber=0, likeNumber=78, createdTime=2017-05-07, rootId=0, userName=luckyshitiancai_42705689, userId=1dc016903257, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=688e9801ee7, moduleTitle=Lancet Respir Med：埃罗替尼与贝伐单抗联合用药使非小细胞肺癌T790M突变患者获益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=688e9801ee7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1582328, encodeId=39f61582328fa, content=<a href='/topic/show?id=020e415e867' target=_blank style='color:#2F92EE;'>#埃罗替尼#</a>, objectTitle=JCO：埃罗替尼、质子泵抑制剂同服，理想再来点可乐, objectType=article, longId=63123, objectId=621163123f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=621163123f0, replyNumber=0, likeNumber=82, createdTime=2016-02-11, rootId=0, userName=luckyshitiancai_42705689, userId=1dc016903257, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=621163123f0, moduleTitle=JCO：埃罗替尼、质子泵抑制剂同服，理想再来点可乐, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=621163123f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1582327, encodeId=0f90158232ed0, content=<a href='/topic/show?id=020e415e867' target=_blank style='color:#2F92EE;'>#埃罗替尼#</a>, objectTitle=JCO：埃罗替尼不能延长NSCLC无病生存时间, objectType=article, longId=56663, objectId=7ba1566636b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ba1566636b, replyNumber=0, likeNumber=86, createdTime=2015-09-29, rootId=0, userName=luckyshitiancai_42705689, userId=1dc016903257, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ba1566636b, moduleTitle=JCO：埃罗替尼不能延长NSCLC无病生存时间, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7ba1566636b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1582326, encodeId=033b158232607, content=<a href='/topic/show?id=020e415e867' target=_blank style='color:#2F92EE;'>#埃罗替尼#</a>, objectTitle=EJC：培美曲塞+埃罗替尼可改善非鳞状NSCLC生存, objectType=article, longId=36798, objectId=18bc36e9818, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18bc36e9818, replyNumber=0, likeNumber=95, createdTime=2014-06-22, rootId=0, userName=luckyshitiancai_42705689, userId=1dc016903257, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18bc36e9818, moduleTitle=EJC：培美曲塞+埃罗替尼可改善非鳞状NSCLC生存, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=18bc36e9818)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

埃罗替尼

2020-05-29

luckyshitiancai_42705689 (审核中...)

前往app查看评论内容

#埃罗替尼#

Lancet Oncol：埃罗替尼+雷莫芦单抗治疗EGFR突变型转移性NSCLC

2019-10-11

luckyshitiancai_42705689 (审核中...)

前往app查看评论内容

#埃罗替尼#

MOL CANCER THER：非小细胞肺癌细胞对EGFR -酪氨酸激酶抑制剂埃罗替尼的敏感性

2017-05-31

luckyshitiancai_42705689 (审核中...)

前往app查看评论内容

#埃罗替尼#

Lancet Respir Med：埃罗替尼与贝伐单抗联合用药使非小细胞肺癌T790M突变患者获益

2017-05-07

luckyshitiancai_42705689 (审核中...)

前往app查看评论内容

#埃罗替尼#

JCO：埃罗替尼、质子泵抑制剂同服，理想再来点可乐

2016-02-11

luckyshitiancai_42705689 (审核中...)

前往app查看评论内容

#埃罗替尼#

JCO：埃罗替尼不能延长NSCLC无病生存时间

2015-09-29

luckyshitiancai_42705689 (审核中...)

前往app查看评论内容

#埃罗替尼#

EJC：培美曲塞+埃罗替尼可改善非鳞状NSCLC生存

2014-06-22

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

#埃罗替尼#

科室

工具

服务